Intellia Therapeutics (NTLA) Granted CRISPR/Cas9 Genome Editing Technology Patent in Europe – StreetInsider.com
|
Intellia Therapeutics (NTLA) Granted CRISPR/Cas9 Genome Editing Technology Patent in Europe
StreetInsider.com Intellia Therapeutics (NASDAQ: NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, announced that the European Patent Office (EPO) has decided to grant a patent broadly … |
